Evidence map›Paper›PMID 40341413›Full record

ArticleOncology reports2025

RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.

Yubo Yan, Xianglong Kong, Xiangyuan Jin, Jianlong Bu, Boxiong Ni, Zuqin Rao, Junnan Guo, Shidong Xu

Abstract read
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yubo YanDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Xianglong KongDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Xiangyuan JinDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Jianlong BuDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Boxiong NiDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Zuqin RaoDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Junnan GuoDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.
Shidong XuDepartment of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ring finger protein 125 (RNF125), a ubiquitin E3 ligase, has been reported to act as a tumor suppressor in several cancers, but its precise function in lung adenocarcinoma (LUAD) has not been elucidated. In the present study, through bioinformatics analysis and immunohistochemistry in LUAD and non‑cancerous samples, it was demonstrated that RNF125 was significantly downregulated in lung cancer. Low levels of RNF125 expression were associated with metastatic status, advanced tumor stage and poor overall survival in LUAD. The results of gain‑ and loss‑of‑function experiments demonstrated that RNF125 inhibited proliferation, colony formation, migration and invasion of LUAD cells. In addition, RNF125 increased the sensitivity of LUAD cells to cisplatin. Mechanistically, RNF125 interacted with programmed cell death ligand 1 (PD‑L1) and reduced PD‑L1 expression levels in LUAD cells. Furthermore, IL‑2 secretion by Jurkat T cells was significantly suppressed when co‑cultured with RNF125‑silenced LUAD cells. NK‑92 cell lysis of RNF125‑silenced LUAD cells was also weaker compared with that of control LUAD cells, suggesting that RNF125 knockdown enhanced the immune evasion ability of LUAD cells. Notably, the results of the present study identified that the RNA‑binding protein muscleblind‑like 1 (MBNL1) is the upstream regulator of RNF125 in LUAD. MBNL1 increased the stability of the RNF125 transcript in LUAD cells and knockdown of RNF125 reversed the antitumor effect of MBNL1 on LUAD cells. In conclusion, the present study demonstrated the tumor suppressor role of RNF125 in LUAD and implicated MBNL1 as an upstream regulator of RNF125 in LUAD. These findings contributed to an improved understanding of the molecular features of LUAD progression.

Indexed as

Adenocarcinoma of LungLung NeoplasmsRNA-Binding ProteinsUbiquitin-Protein LigasesAgedB7-H1 AntigenCell Line, TumorCell MovementCell ProliferationCisplatinDown-RegulationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansMaleB7-H1 AntigenCD274 protein, humanCisplatinRNA-Binding ProteinsUbiquitin-Protein Ligasescisplatinimmune escapelung adenocarcinomamuscleblind‑like 1programmed cell death ligand 1ring finger protein 125

Identifiers

PMID40341413
PMCPMC12075997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.